Table 1.

Approved Shh Pathway Targeting Agents

Drug	Target	FDA Approval Date	EU Approval Date	Disease Indication	Site of Metabolism	Enzymes of Metabolism
ATO	Glil, PML-RARα	9/25/2000	3/5/2002	Acute Promyelocytic Leukemia	Primarily liver, oxidation in various tissues	Primarily methyltransferases
Vismodegib	SMO	1/30/2012	7/12/2013	Locally advanced basal cell carcinoma	Primarily liver	CYP enzymes, in particular CYP2C9, CYP3A4, CYP3A5
Sonidegib	SMO	7/24/2015	8/14/2015	Metastatic or locally advanced basal cell carcinoma basal cell carcinoma	Primarily liver	CYP enzymes, in particular CYP3A